Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Comparative study of hetrombopag vs. eltrombopag in promoting platelet engraftment post-autologous hematopoietic stem cell transplantation: A multicenter clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLiangliang MaHZHanqing Zeng

Discussion

Loading...

Member takes

Overview

Multicenter trial shows hetrombopag improves platelet engraftment in patients post-autologous hematopoietic stem cell transplantation, indicating potential benefits over eltrombopag.

Key Points

  • To compare the clinical efficacy and adverse events of hetrombopag and eltrombopag for platelet engraftment post-auto-HSCT.
  • Conducted a multicenter clinical trial involving 51 patients from eleven transplant centers.
  • Administered hetrombopag or eltrombopag post-autologous stem cell infusion to promote platelet recovery.
  • Assessed adverse events and platelet transfusion requirements during treatment.
  • Hetrombopag significantly accelerates platelet engraftment compared to eltrombopag (12.9 days vs. 17.4 days, p=0.017).
  • Adverse events were mostly mild (grade 1-2) and resolved with supportive care.
  • Platelet transfusion requirements were similar between groups, averaging 2.3 U for hetrombopag and 2.8 U for eltrombopag.

Cite This Study

Ma et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d72ahttps://doi.org/10.1182/blood-2025-7743
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non‐inferiority, randomized controlled trial2022 · 14 citations
  2. 2Use of Eltrombopag to Improve Thrombocytopenia and Transfusion Requirement in Anti-CD19 Car-T Cell-Treated Patients2024
  3. 3Eltrombopag plus G-CSF for peripheral blood stem cell mobilization: Final analysis of a single arm, Phase 2 trial2025
  4. 4Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients2024 · 3 citations
  5. 5Avatrombopag improves platelet engraftment after haploidentical hematopoietic stem cell transplantation: A randomized, double-blind, multicenter, placebo-controlled trial2025